Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT05360238 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Start date: May 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

NCT ID: NCT05349266 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Start date: March 18, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I, single center study to assess the efficacy and safety of ThisCART19A in adult with Non-Hodgkins Lymphoma in China.

NCT ID: NCT05348889 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma (Disorder)

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Start date: August 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

NCT ID: NCT05346809 Recruiting - Multiple Myeloma Clinical Trials

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

NCT ID: NCT05338931 Recruiting - Clinical trials for B-cell Non Hodgkin Lymphoma

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Start date: March 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

NCT ID: NCT05336409 Recruiting - Clinical trials for Indolent Non-Hodgkin Lymphoma

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ELiPSE-1
Start date: January 24, 2023
Phase: Phase 1
Study type: Interventional

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

NCT ID: NCT05332054 Enrolling by invitation - Lymphoma Clinical Trials

Long-Term Follow-up Study

LTFS
Start date: March 16, 2022
Phase:
Study type: Observational

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

NCT ID: NCT05326243 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Start date: May 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

NCT ID: NCT05322330 Recruiting - Clinical trials for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma

NCT ID: NCT05320640 Recruiting - Clinical trials for Advanced Solid Tumors

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Start date: March 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.